Purpose: Sever e cytopenia and liver dysfunction ar e char acter ized as antiepileptic dr ug (AED) adverse effects dependent upon an idiosyncrasy. However, in clinical practice, we often find hematological and biochemical changes during AED treatment with causes other than an idiosyncrasy. This study aims to investigate the effect of antiepileptic monotherapy on hematological and biochemical parameters. Methods: We r etr ospectively r ecr uited 480 patients untr eated with AED at baseline. Changes in hematological and biochemical parameters before and after initiation of medication were investigated, and correlation with plasma concentrations of AED was analyzed. Results: Sixty-six of 480 patients treated with carbamazepine (CBZ: n = 27), sodium valproate (VPA: n = 19) or levetiracetam (LEV: n = 20) monotherapy were eventually selected for analysis. After CBZ treatment, decreased white blood cell (WBC) count and increased gamma-glutamyltransferase (GGT) and alkaline phosphatase (ALP) activities were recorded at high frequencies. Decreased WBC count tended to correlate with elevated serum CBZ level. Elevated GGT activity was observed in all patients treated with CBZ. In patients treated with VPA, platelet (PLT) counts decreased. In patients treated with LEV, there were no significant differences in the measured parameters before and after medication. Discussion: We consider ed that the r eduction in WBC count might be dose-dependently related to AEDs. Elevated GGT activity was observed in all patients treated with CBZ, but the average increase in GGT activity was 35.19 ± 33.08 U/L. In patients undergoing VPA treatment, decreased PLT counts were also observed at high frequency. Thus, hematological and biochemical parameters should be closely monitored in patients receiving AED, especially in patients treated with high doses of AEDs. 
Introduction
Antiepileptic drugs (AEDs) are frequently used for several conditions including epilepsy, psychiatric disorders, and neuropathic pain. In particular, AEDs are essential for the treatment of patients with epilepsy. The goal of AED treatment is to optimize seizure control and quality of life while minimizing treatment toxicity [1] . Appropriate pharmacological management can result in freedom from seizures in 60%-70% of the patients, with more than 90% of them being controlled by monotherapy [2] .
However, various AED side effects have been reported. Commonly occurring side effects of AEDs are drowsiness, dizziness, weight changes, nausea, memory problems, drug eruption, tremors, impaired liver function, pancytopenia, gastrointestinal symptoms, osteoporosis, depression, among other symptoms. In 10% of the patients treated with carbamazepine, adverse reactions are noted, including allergic rashes or leukopenia [3] . AEDs are associated with 8.3% of reports of drug-induced liver injury, which is the major reason for their withdrawal from therapeutic use [4] . The "Patients with Epilepsy Practice Guideline 2018 in Japan" describes the mechanism of AED side effects as usually divided into three types: depending on an idiosyncrasy, dose-dependence, and long-term pharmacotherapy [5] . Cytopenia and liver dysfunction are classified as adverse effects depending on an idiosyncrasy. However, in clinical practice, hematological and biochemical changes caused by AEDs are encountered more often than reported. Several previous reports have described the hematological and biochemical changes caused by AEDs, but these reports included patients on AED polytherapy and compared the hematological and biochemical parameters between control patients and patients with epilepsy. There are few reports that analyzed hematological and biochemical changes caused by AEDs including only patients who were initially untreated with AED and then treated with AED monotherapy. In our longitudinal study, we analyzed the effects of AEDs on hematological and biochemical parameters of patients untreated with AEDs at baseline.
Patients and Methods

Participants
This study was approved by the Ethics Committee of Tokyo Medical and Dental University (#556). We retrospectively recruited 480 patients untreated with AED at baseline in the Department of Neurosurgery, Tokyo Medical and Dental University between April 2012, and December 2017, and in the Hara Clinic between January 2000 and December 2017. Both facilities were accredited by The Japan Epilepsy Society. All the patients selected for this study were untreated with any AED at the first medical examination blood sampling. In six patients, a mean of 1945 ± 3135 (73-8269) days had elapsed since the discontinuation of AED medication; the remaining patients were never exposed to AEDs previously. All enrolled patients were subsequently treated with AED monotherapy.
Data
We longitudinally investigated hematological and biochemical parameters twice in each patient receiving AED monotherapy. Initially, we collected data of a patient within 3 months before AED initiation. From the same patient, we collected hematological and biochemical parameters and AED plasma concentrations from 2 weeks to 3 months after AED initiation. Hematological parameters included white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), and platelet count (PLT). Patients taking folic acid were excluded from hematological analysis because folic acid is associated with the production of blood cells. Biochemical parameters included measurements of aspartate aminotransferase activity (AST), alanine aminotransferase activity (ALT), gamma-glutamyltransferase activity (GGT), alkaline phosphatase activity (ALP), lactate dehydrogenase level (LDH), blood urea nitrogen concentration (BUN), and creatinine (CRE). Patients aged 18 years and under were excluded from liver function evaluation of AST, ALT, GGT, ALP and LDH analysis because these reference values differ between adults and children. Hematological and biochemical parameters were compared between before and after administration of AED. For the hematological and biochemical parameters that showed significant differences, the rates of change (post-/ pre-medication) were calculated, and we analyzed whether these differences correlated with AED plasma concentrations.
Statistics
Data were analyzed using SPSS version 25 (IBM Corp., Armonk, NY, USA). Paired ttest was used for the analyses of continuous data, comparing pre-with post-medication data. Correlation between the rates of change in parameters and AED plasma concentrations was assessed using Pearson's correlation coefficient. For non-normally distributed data, Wilcoxon signed rank test, and Spearman's correlation coefficient were used. A two-sided P < 0.05 was considered statistically significant. 
Results
A flow chart of patient selection is presented in Figure 1 . A total of 480 patients were recruited, who were not treated with AED at baseline and began AED monotherapy at the beginning of this study period. Three hundred of the 480 patients (63%) were excluded because of comorbidities comprising cancer (n = 130), traumatic brain injuries (n = 128), cerebrovascular disease (n = 11), convulsive attacks (n = 11), cerebral fracture (n = 5), cerebral abscess (n = 5), liver or renal dysfunction (n = 4) and other comorbidities (n = 6). The reason for exclusion is that blood cell counts or liver enzyme levels may be influenced by chemotherapy, immunosuppressive drugs, acute stress, surgical wound infection, or co-administered drugs. Thirteen of the 480 patients (3%) were further excluded because of discontinuation of AED or change in AED within two weeks after initiation of the first AED: carbamazepine (CBZ, eight patients), sodium valproate (VPA, three patients), levetiracetam (LEV, one patient) and lacosamide (LCM, one patient). Six of 13 patients discontinued AED treatment for reasons other than side effects, such as discontinuation of hospital visit and poor adherence. The remaining seven patients changed to another AED because of side effects. Hypacusis (n = 1), drowsiness (n = 1), or dizziness (n = 3) were reported in five patients treated with CBZ, while drug eruption (n = 1) and decreased WBC count (n = 1) were reported in two patients initiated with VPA. The blood sampling time points before and after AED medication were designated "pre-medication" when sampled within three months from initiation of AED medication and "post-medication" when sampled from 2 weeks to 3 months after initiation of AED therapy. The case of increasing AED dosage was regarded as an exception in this criterion related to the blood sampling time points. Ninety-one of 480 patients (19%) were excluded because of no blood sampling at the designated time points. Four patients were excluded due to other factors such as pregnancy (n = 2), hemolysis (n = 1), and abnormal AST level before AED medication. (n = 1). Seventy-two of 480 patients (15%) remained for further analysis. Eventually, we selected 66 patients treated with CBZ, VPA or LEV monotherapy for final analysis (CBZ: n = 27, VPA: n = 19, LEV: n = 20) (Table 1) . Six patients were excluded from analysis because of insufficient patient numbers for AED monotherapy (phenytoin: n = 1, lamotrigine: n = 3, zonisamide: n = 2). Of 66 patients, 36 patients had localization-related epilepsy, 18 exhibited generalized epilepsy, five patients were unknown, one patient was diagnosed with bipolar disorder, and six patients were treated with AED for convulsion prevention. According to patient medical records, 28 of 66 patients were prescribed medications other than AED, which included medications administered only occasionally. All patients included were deemed otherwise healthy at blood sampling. CBZ One patient taking folic acid was excluded from analysis. Finally, hematological parameters were analyzed in 26 patients. Postmedication WBC counts were significantly lower compared with pre-medication WBC counts (pre-medication 6.24 ± 1.90×10 3 /µL, post-medication 5.28 ± 1.56×10 3 /µL, P < Number of patients treated with folic acid, n (%) 5 (7) 1 (4) 3 (16) 1 (5) correlate with post-medication plasma concentration, but this effect was not significant, as shown in Figure 2 (Pearson's correlation coefficient, R = -0.38, P = 0.056). As CBZ plasma concentration increased, WBC count tended to decrease. On the other hand, the rates of GGT and ALP changes did not correlate with post-medication plasma CBZ concentration.
VPA
Post-medication PLT count was significantly lower (pre-medication 24.17 ± 6.87×10 4 /µL; post-medication 20.71 ± 6.31×10 4 /µL, P = 0.006) ( 
LEV
There were no significant differences in the measured parameters between pre-and postmedication values (Table 4) following LEV treatment. The mean post-medication plasma concentration was 10.68 ± 10.16 µg/mL (n = 16).
Discussion
This study is retrospective. Therefore, the number of patients varied in different parameters measured and the number of patients studied was not large. However, the subjects included in this study were AED-untreated patients who initiated AED monotherapy, and did not possess complicating factors that would affect liver function or blood cell counts.
In our study, WBC counts significantly decreased after CBZ treatment in 69% of the patients. An observed WBC reduction in 3.7% of patients has been previously reported [6] . However, this figure might indicate patients who had lower WBC counts than the reference value. In this study, WBC count decreased at a higher frequency than previously reported and none of the patients had WBC count lower than the lower reference limit (3.5×10 3 to 9.7×10 3 /µL) after initiation of CBZ treatment. Bachmann et al. [7] showed a statistically significant increase in WBC count in women administered CBZ (P = 0.039) compared with controls. Conversely, our study evaluated the hematological changes before and after medication in identical patients. Moreover, we revealed that the rate of WBC change tended to correlate with post-medication plasma CBZ concentration. Also, because we excluded patients who discontinued AED within two weeks after AED initiation, patients with side effects depending on an idiosyncrasy may have been excluded from our analysis. Our results suggest a potential mechanism other than allergy or drug toxicity to account for these observations. Huang et al. [8] suggested that the serum levels of folate and vitamin B12 following AED treatment were significantly lower than those before AED treatment. It is well known that folate and vitamin B12 are necessary for DNA synthesis. In our study, hematological changes other than blood cell counts were not revealed. Also, the absence of measured folate and vitamin B12 data impeded us from investigating those changes. However, there is a possibility that low serum levels of folate and vitamin B12 caused by AED resulted in the observed high frequency of WBC count reduction. We found that decreased WBC counts were frequently induced by CBZ treatment. Because WBC subsets were not investigated, we should prospectively monitor WBC subsets of patients treated with CBZ in future studies.
CBZ has been described as a potent inducer of microsomal enzymes in the liver [9] . Liver enzymes induced by CBZ have been previously documented [10] . However, there are few reports of the relationship between enzyme induction and a concrete upper limit of elevated GGT activity. In our report, a patient with GGT level of 171 U/L showed no clinical symptoms of liver dysfunction.
The frequency of elevated GGT has been widely reported to be 34%-100% in patients undergoing CBZ treatment [11] [12] [13] . Strolin et al. [10] reported that increase in serum GGT was generally observed in 75%-95% of patients treated chronically with enzymeinducing agents. In our study, GGT activities were higher in all patients treated with CBZ compared with pre-medication levels. According to Callaghan et al. [14] , GGT and ALP should not be regarded as indicators of hepatocellular damage in patients taking anticonvulsant drugs, because increased levels of these enzymes may reflect enzyme induction rather than lesions of the cells. We considered that the increased GGT and ALP activi-ties observed in our study resulted from liver enzyme induction by CBZ treatment.
Isojärvi et al. [15] has reported that progressive increase in serum GGT activity during the first five years of CBZ medication is common. They also demonstrated that after two months of CBZ treatment, significantly elevated GGT activity was observed compared with that measured before treatment, which is consistent with our result. However, they did not report whether GGT activity was elevated to above normal value. In our study, GGT activity was elevated in all patients treated with CBZ, and GGT activity exceeded the reference values in 33% of the patients treated with CBZ. Isojärvi et al. [15] also revealed that longer CBZ treatment resulted in higher GGT activity. Therefore, patients undergoing long-term treatment with CBZ require follow-up.
Nijhawan et al. [16] reported that among 13 patients on AED therapy (PHT, PB or CBZ) with increased serum ALP activity, 12 had increased liver ALP isoenzyme activity, but nine had normal bone ALP isoenzyme activity. According to the authors, the induction of liver microsomal enzymes by AEDs could include liver ALP, but not bone ALP [16] . However, patients administered CBZ exhibited significantly elevated ALP levels accompanied by increased bone and liver isoenzyme activities compared with controls [17] . Thus, in our study, elevated ALP may occur not only in the liver but also in bone. Previous studies found no correlation between dosage of CBZ and changes in biochemical parameters [18] , which is consistent with the present finding. Rehimdel et al. [18] also revealed that the duration of CBZ treatment correlated with increased ALP activity.
However, in our study, the relation between the duration of CBZ use and the changes in biochemical parameters was not evaluated. As patients with epilepsy often undergo longterm AED therapy, we should regularly monitor biochemical parameters of these patients even in those prescribed a low dosage of AED. In our study, 14 of 16 patients treated with VPA (88%) demonstrated decreased PLT counts after VPA therapy was initiated. However, PLT counts were lowered to 13×10 4 /µL in only one of 16 patients (6%). In a previous study, thrombocytopenia was present (PLT count ≤ 13×10 4 /µL) in 12 of 60 patients (20%) [19] . Another report suggested that 17.7% of patients experienced thrombocytopenia (PLT count ≤ 10×10 4 /µL) after exposure to divalproex sodium [20] . Mean plasma VPA concentration in this study was 36.3 µg/mL, which was lower compared with the concentration of 79.6 µg/ml in a previous report [20] . The PLT count may infrequently decrease to lower than 13×10 4 /µL because of low VPA plasma concentration. However, a study reported that prominent hematologic abnormalities including thrombocytopenia, macrocytosis, anemia, and leukopenia increased to 55% in 22 patients with VPA levels > 100 µg/mL compared with 33% of the total number of patients treated with VPA [19] . Thus plasma VPA concentration should be carefully monitored particularly in patients treated with high doses of VPA . According to the literature, elevated serum vitamin B12 and no change or elevated folate concentrations occur after VPA treatment [21 -23] . Hauser et al. [21] reported thrombocytopenia, macrocytosis, increased serum vitamin B12 and a significant downward trend in red blood cell count after initiation of VPA thera-py, and suggested the possibility that direct toxic effect on hematopoietic precursor or stem cell was responsible for these effects. Acharya and Bussel [24] also reported that VPA caused bone marrow suppression, resulting in hematologic toxicity. However, in our study, there was no other hematological change apart from decreased PLT count, possibly because of the small number of patients administered VPA.
In this study, there were no changes in measured biochemical parameters in patients after VPA treatment. There are several reports of alterations in liver enzymes in patients treated with VPA. Cepelak et al. [12] described increased AST, ALT, and GGT activities in patients administered VPA compared with healthy children. In vitro VPA treatment has been demonstrated to induce enzyme production [25] . In contrast, Hauser et al. [21] reported no significant upward trends in mean AST, ALT, GGT, and ALP levels, but a significant decline in ALT at 3 and 6 months after VPA treatment. In the present study, there were no changes in these levels following VPA treatment, but this might be due to the relatively small sample size.
LEV is a drug widely used for treating patients with epilepsy because of its superior tolerability and efficacy. Whether LEV causes hematological changes is controversial. Neutropenia, decreased lymphocyte count, or thrombocytopenia induced by LEV has been reported [26] [27] [28] [29] [30] , while Dinopoulos et al. [26] reported decreased lymphocyte count with no decrease in total WBC count. In our study, there were no significant differences between pre-and post-treatment values in all the hematological parameters examined in patients administered LEV. A larger study is required to clarify the effects of LEV on hematological parameters.
The major metabolic pathway of LEV does not depend on the hepatic cytochrome P450 system, and LEV does not induce hepatic enzymes [31] . Therefore, LEV does not influence liver function. In our study, there were no changes in liver enzymes, consistent with previous reports.
Conclusions
After CBZ treatment, WBC count decreased in 69% of patients while GGT and ALP activities increased in 85%. Decreased WBC count tended to correlate with elevated serum CBZ level. Therefore, our results suggest that hematological changes are dosedependently related to AED concentrations. The high frequencies of elevated GGT and ALP activities may be caused by induction of liver microsomal enzymes by AEDs. Decreased PLT count was observed in 88% of patients who initiated VPA. Hematological and biochemical parameters should be carefully monitored in patients undergoing AED treatment, especially in those treated with high AED doses.
